Chiltern Announces Collaboration with Dr. Nawab Qizilbash of OXON Epidemiology
London, UK
Chiltern International Limited (Chiltern) has announced a collaboration with Dr Nawab Qizilbash of OXON Epidemiology.
Dr. Nawab Qizilbash, MBChB, BSc, MRCP (UK), MSc, Phil (Oxon) is the Director of OXON Epidemiology Ltd. He served as Director of Epidemiology and Evidence-based Medicine at GlaxoSmithKline. Formerly an Honorary Consultant Physician/Senior Research Fellow at Radcliffe Infirmary, Oxford University, Nawab trained under Professor Sir Richard Peto F.R.S. in epidemiology, Phase IV trials and meta-analysis. He also collaborates with Professor Stephen Evans in academic research on statistical signal detection.
Dr Qizilbash has authored 5 publications in the Lancet, one in the Journal of the American Medical Association and one in the British Medical Journal, among others. He founded the Cochrane Dementia Group and is chief editor of an international textbook on clinical dementia.
Jane Turner, MRPharmS, Chiltern’s Late Phase Director, Europe, stated, “We are delighted to announce the alliance between Chiltern Late Phase and Dr. Nawab Qizilbash and his company, OXON Epidemiology Ltd. OXON is a niche consultancy company that specializes in ‘real world data’: epidemiology, risk management, and health economics. This partnership will allow Chiltern to provide epidemiology and outcomes research expertise in conjunction with flexible and bespoke late phase study solutions to our sponsors.
Dr. Qizilbash commented, “OXON is delighted to be collaborating with Chiltern Late Phase. The combination provides scientific strength with breadth and global reach to late phase, allowing for strategic consulting, planning and implementation of: observational studies, risk management, health economics and Phase IV trials.”
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
